|
Helping you map the right way forwardPharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by these changes. Through the Ernst & Young’s Global Life Science Center, we bring together a worldwide team of industry professionals to help you achieve your potential — a team with deep experience in providing assurance, tax, transaction and advisory services to pharmaceutical companies around the globe. It’s a team that works to anticipate market trends and their implications, so you receive practical advice on the right way forward for your organization.We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues specific and often unique to the biotech sector, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the business of improving people's health. Whether it’s forming the right alliances, addressing the changing pharmaceutical business model, improving operations, enhancing your reputation or gaining insights into the market, we can give you a clear perspective on how to drive value in today’s complex, competitive and risk-driven environment. | Life sciences insights: changing times In this issue of our quarterly, Life science insights, we explore the current dynamics of the global financial crisis (pdf, 384kb) and its impact on the life sciences industry, the emergence of risk evaluation mitigation strategies (REMSs) mandated by the Food and Drug Administration and the deregulation of pharmacies and over-the-counter medications in Europe. Read our perspective on these topics and their impact on our ever-changing industry. Insights into the pharmaceutical industry in emerging markets As the financial crisis continues its impact on the global marketplace, what are the challenges and opportunities facing pharmaceutical companies in the emerging markets? (pdf, 400kb) . This engaging topic was discussed during Ernst & Young’s Global Pharmaceutical Center’s recent launch of our annual report, Progressions, in Brazil, Mexico, Japan and China. Read insights from our discussions with pharma industry leaders in each country. Supply chain risks reaching peak levels amid global financial crisis With today’s economic turmoil, financial viability of some suppliers may be at risk. As pharmaceutical companies rely on an increasingly complex "extraprise" of suppliers, monitoring suppliers' financial health and identifying warning signs will be critical. Even well-run suppliers may experience discontinued credit or other liquidity challenges. And demise may be quick – in weeks or even days. Discover measures for monitoring risk and protecting stakeholder value (pdf, 82kb). Lessons from change: the life sciences industry How can you manage your company through the recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified some overarching themes. From managing risks to improving capital allocation, we reveal the lessons that could mean the difference between surviving and thriving in the new economic environment. |
| |
|
/$FILE/14L00194.JPG)